Cargando…
Sirolimus for patients with progressive epithelioid hemangioendothelioma
Epithelioid hemangioendothelioma is an ultrarare soft tissue sarcoma with limited literature to guide treatment. The results from a robust retrospective cohort study support the use of sirolimus for patients who have multifocal epithelioid hemangioendothelioma without serosal effusion.
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7894141/ https://www.ncbi.nlm.nih.gov/pubmed/33107994 http://dx.doi.org/10.1002/cncr.33246 |
| _version_ | 1783653185265598464 |
|---|---|
| author | Smrke, Alannah M. Huang, Paul H. Jones, Robin L. |
| author_facet | Smrke, Alannah M. Huang, Paul H. Jones, Robin L. |
| author_sort | Smrke, Alannah M. |
| collection | PubMed |
| description | Epithelioid hemangioendothelioma is an ultrarare soft tissue sarcoma with limited literature to guide treatment. The results from a robust retrospective cohort study support the use of sirolimus for patients who have multifocal epithelioid hemangioendothelioma without serosal effusion. |
| format | Online Article Text |
| id | pubmed-7894141 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | John Wiley and Sons Inc. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-78941412021-03-02 Sirolimus for patients with progressive epithelioid hemangioendothelioma Smrke, Alannah M. Huang, Paul H. Jones, Robin L. Cancer Editorials Epithelioid hemangioendothelioma is an ultrarare soft tissue sarcoma with limited literature to guide treatment. The results from a robust retrospective cohort study support the use of sirolimus for patients who have multifocal epithelioid hemangioendothelioma without serosal effusion. John Wiley and Sons Inc. 2020-10-27 2021-02-15 /pmc/articles/PMC7894141/ /pubmed/33107994 http://dx.doi.org/10.1002/cncr.33246 Text en © 2020 The Authors. Cancer published by Wiley Periodicals LLC on behalf of American Cancer Society. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
| spellingShingle | Editorials Smrke, Alannah M. Huang, Paul H. Jones, Robin L. Sirolimus for patients with progressive epithelioid hemangioendothelioma |
| title | Sirolimus for patients with progressive epithelioid hemangioendothelioma |
| title_full | Sirolimus for patients with progressive epithelioid hemangioendothelioma |
| title_fullStr | Sirolimus for patients with progressive epithelioid hemangioendothelioma |
| title_full_unstemmed | Sirolimus for patients with progressive epithelioid hemangioendothelioma |
| title_short | Sirolimus for patients with progressive epithelioid hemangioendothelioma |
| title_sort | sirolimus for patients with progressive epithelioid hemangioendothelioma |
| topic | Editorials |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7894141/ https://www.ncbi.nlm.nih.gov/pubmed/33107994 http://dx.doi.org/10.1002/cncr.33246 |
| work_keys_str_mv | AT smrkealannahm sirolimusforpatientswithprogressiveepithelioidhemangioendothelioma AT huangpaulh sirolimusforpatientswithprogressiveepithelioidhemangioendothelioma AT jonesrobinl sirolimusforpatientswithprogressiveepithelioidhemangioendothelioma |